Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, multicenter, parallel-group, equivalence study involving
about 462 clinically stable hemodialysis patients aged 18 years or above suffering from
anemia and treated previously with a stable dose of ERYPO® intravenously.